ANMI SA is a precursor supplier for radiometal labeled radiopharmaceuticals and a global service provider in the nuclear medicine field, located in Liège, Belgium.
ANMI has developed innovative solutions to facilitate the synthesis of these theranostic radiopharmaceuticals and to ease their daily production in hospitals. These solutions are scalable and adaptable to a large range of peptide and non-peptide-based radiopharmaceutical precursors.
The company's expertise is based on a strong market and regulatory knowledge of the nuclear medicine areaand can provide premium quality products and services.
ANMI's vision is focused on increasing patient access to new highly specific theranostic radiopharmaceuticals through straight forward and cost effective production processes.